BiotechTube
Iltoo Pharma

Iltoo Pharma

Paris, France· Est.
iltoopharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Iltoo Pharma is a private, preclinical-stage biotech based in Paris, developing novel biologics targeting regulatory T cells to restore immune tolerance in autoimmune and inflammatory diseases. The company's leadership features a world-class Scientific Advisory Board with deep expertise in immunology and clinical development, and its strategy is built on valuable partnerships. While currently pre-revenue, Iltoo is targeting high-unmet-need conditions like ALS, positioning itself in the rapidly evolving field of immunomodulation.

Autoimmune DiseasesNeuroimmune DiseasesInflammatory DiseasesAmyotrophic Lateral Sclerosis

Technology Platform

Platform focused on developing biologics that modulate Regulatory T cells (Tregs) to restore immune tolerance and treat autoimmune, neuroimmune, and inflammatory diseases. Likely involves cytokine modulation or targeted activation of Treg pathways.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The global autoimmune and neurodegenerative disease markets represent multi-billion dollar opportunities with high unmet need.
A successful Treg-modulating platform could be applied across a wide spectrum of diseases, creating multiple shots on goal.
Validating the approach in ALS, a condition with few options, could lead to breakthrough therapy designation and accelerated pathways.

Risk Factors

High scientific risk in translating Treg biology into a safe and effective therapy, especially in a complex disease like ALS.
Financial risk as a pre-revenue company dependent on external funding.
Intense competition from larger biopharma companies also pursuing immune tolerance strategies.

Competitive Landscape

Iltoo operates in the competitive field of immunomodulation, facing rivals ranging from large pharma (e.g., with IL-2 variants, co-stimulation modulators) to biotechs developing Treg-focused cell therapies and biologics. Its differentiation lies in its specific scientific approach and elite academic foundation, but it will need to demonstrate clear preclinical and clinical advantages.

More companies in Biologics / Biosimilars →More companies in France →